[Translation] A single-center, randomized, open-label, single-dose, two-formulation, two-cycle, two-sequence, two-crossover bioequivalence trial of oseltamivir phosphate granules in healthy Chinese subjects under fasting and postprandial conditions.
本试验以安徽省先锋制药有限公司提供的磷酸奥司他韦颗粒(规格:0.9g(按C16H28N2O4计))为受试制剂,以中外製薬株式会社持证的磷酸奥司他韦干糖浆(商品名:Tamiflu®,规格:3%(30g)(按C16H28N2O4计))为参比制剂,分别考察空腹和餐后状态下受试制剂与参比制剂在健康试验参与者体内的药代动力学参数,评价两制剂的生物等效性。
[Translation] This study used oseltamivir phosphate granules (specification: 0.9g (calculated as C16H28N2O4)) provided by Anhui Xianfeng Pharmaceutical Co., Ltd. as the test formulation, and oseltamivir phosphate dry syrup (trade name: Tamiflu®, specification: 3% (30g (calculated as C16H28N2O4)) certified by Chugai Pharmaceutical Co., Ltd. as the reference formulation. The pharmacokinetic parameters of the test formulation and the reference formulation in healthy participants under fasting and postprandial conditions were investigated to evaluate the bioequivalence of the two formulations.